Accellix
Accellix develops an automated benchtop flow cytometry platform with single-use microfluidic cartridges for rapid cell phenotyping quality control inside cell and gene therapy GMP manufacturing suites, serving biopharmaceutical manufacturers and blood banks. Acquired by bioMérieux in January 2026.
- Company typePrivate
- Founded2017
- HeadquartersJerusalem, Israel
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Accellix does
Accellix, founded in 2017 (originally as LeukoDx, rebranded in July 2019) and headquartered in San Jose, California with R&D operations in Jerusalem, Israel, developed an automated benchtop flow cytometry platform purpose-built for quality control workflows inside cell and gene therapy GMP manufacturing suites. The core product integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system that delivers cell phenotyping results in approximately 30 minutes, eliminating the need for centralized laboratory infrastructure, skilled flow cytometry technicians, and cold-chain reagent logistics. The platform combines a small-footprint fan-less instrument, single-use cartridges containing unitized dried reagents with 12-month room-temperature stability, a 6-color multiparametric assay architecture, and proprietary auto-classification software that dynamically defines cell subset boundaries without hard thresholds. Accellix's go-to-market centered on direct enterprise field sales targeting cell therapy manufacturers (CAR-T, TCR, NK, stem cell, iPSC applications) and blood bank and collection center customers such as the American Red Cross Cell and Gene Therapy Solutions, complemented by an exclusive bioMérieux distribution partnership across China, Japan, Australia, and South Korea. The business model follows a razor-and-blade structure with hardware instrument sales, recurring consumable cartridge revenue, maintenance and service contracts, and custom assay development services, generating revenue from over 20 enterprise biopharmaceutical customers by 2021. In January 2026, bioMérieux acquired 100% of Accellix for approximately €35 million in cash, integrating the platform into its Pharmaceutical Quality Control franchise alongside sterility, mycoplasma, and endotoxin testing offerings for the advanced therapy market.
Accellix firmographics
Firmographics- Name
- Accellix
- Legal name
- Accellix, Inc.
- Website
- https://accellix.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Accellix develops an automated benchtop flow cytometry platform with single-use microfluidic cartridges for rapid cell phenotyping quality control inside cell and gene therapy GMP manufacturing suites, serving biopharmaceutical manufacturers and blood banks. Acquired by bioMérieux in January 2026.
- Ownership category
- akta.pro rank
Accellix industry classification
Industry- Product category
- Flow Cytometry Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)
- akta.pro secondary industries
- Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Accellix is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
Accellix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Instrument Sales: Sale of the Accellix Instrument - a benchtop flow cytometer platform. Instrument includes 12-month warranty from date of installation.
- Assay/Cartridge Consumables: Single-use microfluidic cartridges and assay kits with dried reagents. Each kit provides automated sample preparation, data acquisition and analysis for one cell sample. Assays have 12 months stability at room temperature.
- Maintenance and Service Contracts: Preventive maintenance per year per instrument, onsite service, and technical support. First year included with instrument purchase, subsequent years purchasable at reduced cost.
- Professional Services: Training, maintenance, repairs, and other services as mutually agreed upon per purchase order or quote.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based instrument and consumable pricing |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
Accellix product offering
Product offeringCore offering
Accellix sells an automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system for GMP manufacturing quality control. The platform comprises the Accellix Instrument (hardware), Accellix Software, single-use microfluidic cartridges with dried reagents, and standard/custom assay kits that deliver cell phenotyping results in approximately 30 minutes for cell and gene therapy manufacturers and blood banks.
Product overview
Accellix offers a unified automated cell phenotyping platform consisting of the Accellix Instrument (benchtop flow cytometer hardware), Accellix Software, and Microfluidic Cartridges with integrated dried reagents. The platform automates the complete workflow from sample preparation through flow cytometry acquisition to data analysis, delivering results in under 30 minutes. The product portfolio includes Standard Assay Kits for common markers (T-Cell, Lymphocyte Subset panels) and Custom Assay Kits that can accommodate panels with up to 6 fluorophores. Algorithm-Based Autoanalysis provides automated data classification using proprietary algorithms. All components are designed for GMP manufacturing environments and point-of-need testing.
Differentiator
Problem solved
Functional benefit
Products and services
- Accellix Automated Cell Phenotyping Platform Unified automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based workflow, delivering GMP-compliant QC results in under 30 minutes for cell and gene therapy manufacturers and blood banks.
- Accellix Instrument Small-footprint benchtop flow cytometer platform with touchscreen interface, fan-less operation, 24/7 availability, and ethernet/wifi connectivity, designed for deployment inside GMP manufacturing suites with no calibration or user maintenance required.
- Accellix Software Configurable touchscreen software for QC workflows, including QR-coded cartridge protocol execution, 21 CFR Part 11 compliance, LIMS connectivity, and export of FCS, CSV, and PDF reports.
- Microfluidic Cartridge Single-use microfluidic cartridge with unitized dried-down reagents and integrated fluorescent control beads that perform automated sample preparation, in-run instrument performance checks, and ratio-metric cell counting within a controlled microfluidic flow cell.
- Standard Assay Kits Off-the-shelf fixed-panel assay kits (e.g., T-Cell and Lymphocyte Subset Assays) shipped as single-use microfluidic cartridges with dried reagent tubes and 12-month room-temperature stability for immediate use on the Accellix instrument.
- Custom Assay Kits Bespoke assay development service that migrates customer flow cytometry panels (up to 6 fluorophores) onto the Accellix cartridge format, including n-1 and n-2 proof-of-concept kits, for proprietary cell therapy QC markers.
- Algorithm-Based Autoanalysis Automated data analysis and auto-classification service that uses proprietary algorithms with dynamic boundary definition (no hard thresholds) to identify cell subsets, configured per customer assay requirements.
Quantifiable outcome
- 4-5x improvement in reproducibility when implementing Accellix and automating QC workflow
- +4 more outcomes
Companies that use Accellix
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Accellix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Accellix partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, strategic and core.
- bioMérieuxflagshipbioMérieux acquired 100% of Accellix for approximately €35 million in cash in January 2026, increasing from its prior ~10% stake. The acquisition strengthens bioMérieux's Pharmaceutical Quality Control activity and adds cell purity and viability testing to its existing sterility, mycoplasma, and endotoxin testing portfolio for the advanced therapy market.
- StreckstrategicStrategic collaboration adding the Accellix Automated Cell Phenotyping Platform to Streck's CD-Chex Plus® (RUO) control. The integration allows users to assess Accellix platform performance and ensure reliable operation, supporting routine monitoring in fast-paced manufacturing environments without requiring separate or centralized lab infrastructure.
- American Red Cross Cell and Gene Therapy SolutionscoreAmerican Red Cross selected Accellix to provide instruments and assays at its CGTS collection sites to improve characterization of source materials used for cell therapy development. The Accellix Platform enables high-quality cell therapy source material characterization within 30 minutes at the point of collection, supporting timely shipment of leukopak products with Certificate of Analysis.
- bioMérieux (Asia Pacific)corebioMérieux designated as exclusive distributor of Accellix products in China, Japan, Australia, and South Korea. bioMérieux performs full range of sales, supply, and service activities in the Asia Pacific region. The partnership builds on bioMérieux's portfolio of ATMP quality control solutions.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Accellix competitors and assessment
Company assessmentDirect peers
- Beckman Coulter Life Sciences: Major flow cytometry provider owned by Danaher, offering benchtop and high-end flow cytometers and cell sorting systems. Directly competes with Accellix in flow cytometry instrumentation with established presence in cell therapy and bioprocess QC markets.
- BD Biosciences: Becton Dickinson's life sciences arm offers flow cytometry instruments (BD FACSCelesta, BD FACSDiscover) and a broad reagent portfolio for cell analysis. Competes with Accellix in providing flow cytometry solutions to cell therapy manufacturers and research laboratories.
- Cytek Biosciences: Specializes in spectral flow cytometry platforms (Aurora, Northern Lights) with full-spectrum capabilities for high-parameter cell analysis. Competes with Accellix in the flow cytometry instrumentation market serving immunology and cell therapy research.
- Miltenyi Biotec: Provides cell therapy manufacturing tools including the MACSQuant flow cytometer and integrated cell processing platforms. Directly competes with Accellix by offering flow cytometry and cell analysis solutions tailored to cell and gene therapy manufacturing workflows.
- Sony Biotechnology: Offers cell sorters and flow cytometers (SH800, MA900) used in cell therapy manufacturing and research. Competes with Accellix in providing flow cytometry solutions with GMP-friendly features for cell therapy applications.
Broad incumbents
- Thermo Fisher Scientific: Major life sciences tools provider offering flow cytometry instruments (Attune, Bigfoot) alongside extensive reagent and cell therapy manufacturing portfolios. Provides overlapping capabilities to Accellix but as part of a much broader life sciences business.
Emerging players
- NanoCellect Biomedical: Developer of microfluidic cell sorting and analysis platforms for cell therapy and biomedical research. Competes with Accellix in providing microfluidic-based flow cytometry tools targeting cell therapy manufacturing QC.
- De Novo Software: Specializes in flow cytometry data analysis software (FCS Express) used by cell therapy and immunology researchers. Adjacent to Accellix as a software-focused competitor offering automated cell analysis capabilities.
- Curiox Biosystems: Offers automated, microfluidic-based cell analysis platforms (DropArray, Laminar Wash) for immunology and cell therapy research. Competes with Accellix by providing miniaturized, automated cell phenotyping solutions with reduced manual handling.
Others
- Streck: Provider of quality control materials and hematology controls for clinical and research labs. Strategic collaboration partner with Accellix integrating CD-Chex Plus control with the Accellix platform; serves an enabling role rather than direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Accellix social profiles
Digital presenceAccellix compliance and trust
Trust signalCompliance2 records
Accellix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accellix leadership team
Management profileNumber of profiles
Profiles9 records
Accellix funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accellix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accellix
What does Accellix do?
Accellix sells an automated benchtop flow cytometry platform that integrates sample preparation, flow cytometry acquisition, and data analysis into a single microfluidic cartridge-based system for GMP manufacturing quality control. The platform comprises the Accellix Instrument (hardware), Accellix Software, single-use microfluidic cartridges with dried reagents, and standard/custom assay kits that deliver cell phenotyping results in approximately 30 minutes for cell and gene therapy manufacturers and blood banks.
Is Accellix a public or private company?
Accellix is a private company. It is classified as corporate owned and is currently acquired.
When was Accellix founded?
Accellix was founded in 2017. It employs 51 to 100 people.
Where is Accellix based?
Accellix is headquartered in Jerusalem, Israel, in the Middle East region.
How does Accellix make money?
Four revenue lines are on record. Instrument Sales are the primary driver. The others are assay/Cartridge Consumables, maintenance and Service Contracts and professional Services.
Who are Accellix's main competitors?
Direct peers on record are Beckman Coulter Life Sciences, BD Biosciences, Cytek Biosciences, Miltenyi Biotec and Sony Biotechnology. Thermo Fisher Scientific is listed as a broad incumbent. Emerging players are NanoCellect Biomedical, De Novo Software and Curiox Biosystems. Streck is listed as an others.
Does Accellix have an API?
No public API is recorded for Accellix.
What industry is Accellix in?
Accellix's product category is Flow Cytometry Instrumentation. Its primary akta.pro industry code is HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics), with a secondary code of HLAGAIAD, Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations). Its NAICS code is 334516 and its SIC code is 3826.